E.H. Douma

Business Developer at Parkinnova Therapeutics (the Netherlands)

[E.H. Douma @ehdouma]

🚨 Excited to share that our latest research is now published in Cell & Bioscience!

We found that PDE inhibition and GUCY2C activation enhances motor function in #ParkinsonsDisease

📄 Read the full paper: https://t.co/slRq5C4N75

@SILS_UvA @parkinnova

#Neuroscience

[E.H. Douma @ehdouma]

🚀Parkinnova's first publication is now online in @TrendsMolecMed: https://t.co/QxsDG8xCHC.

📰Discover the biomolecular background of our innovative strategy for treating Parkinson's disease🧠.

https://t.co/vSGzLmB1vz

#Parkinsons @SILS_UvA @LarsPvanderHei1 @Parkinnova

[E.H. Douma @ehdouma]

🧠📢 The first publication of Macrobian Biotech (https://t.co/8mz15hn3g1) is out in
@JNeurochem! It's about the regulation of the rate-limiting enzyme in dopamine synthesis: tyrosine hydroxylase. Find out more: https://t.co/BkAtrh7P3G

@SILS_UvA @LarsPvanderHei1 #Parkinson

[E.H. Douma @ehdouma]

My first research paper is now online!

Together with em. prof. dr. E. Ronald de Kloet, I wrote a review article titled "Stress-induced plasticity and functioning of ventral tegmental dopamine neurons".

The article is open access and can be found here:
https://t.co/3JNgCaQuJR

[The Science of Parkinson's @ScienceofPD]

Interesting report highighting the importance of Mcl1 - a critical Bcl2 pro-survival factor - for dopamine neurons (a group of cells that are particularly affected in #Parkinsons)
https://t.co/2S97jkMtLd